# Section XXX Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML)

This section includes Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML). In the 3rd edition of the International Classification of Diseases for Oncology, the behavior code of myelodysplastic syndromes and chronic myeloproliferative disorders was changed from /1, borderline malignancy or low malignant potential, to /3, malignant primary site. These diagnoses became reportable for cases diagnosed in 2001+ when ICD-O-3 went into effect. CMML has been reportable for all years. CMML is included here and in the leukemia section.

#### MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOPROLIFERATIVE DISORDERS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA

## Counts, Percents and Age-Adjusted Incidence Rates<sup>a</sup> for the 17 SEER Geographic Areas by Subtype, 2001-2004

		Both Sexes			Males			Females		
Site	Count	Percent	Rate	Count	Percent	Rate	Count	Percent	Rate	
Total	17410	100.0%	6.1	9421	100.0%	8.0	7989	100.0%	4.9	
Myelodysplastic syndromes (MDS)	10268	100.0%	3.6	5564	100.0%	4.9	4704	100.0%	2.9	
Refractory anemia (RA), NOS	1657	16.1%	0.6	839	15.1%	0.7	818	17.4%	0.5	
RA with ringed sideroblasts	1169	11.4%	0.4	627	11.3%	0.6	542	11.5%	0.3	
RA with excess blasts (RAEB)	1382	13.5%	0.5	833	15.0%	0.7	549	11.7%	0.3	
RAEB in transformation	151	1.5%	0.1	85	1.5%	0.1	66	1.4%	0.0	
Refractory cytopenia w/multilineage dysplasia	409	4.0%	0.1	243	4.4%	0.2	166	3.5%	0.1	
Myelodysplastic syndrome with 5q deletion	169	1.6%	0.1	70	1.3%	0.1	99	2.1%	0.1	
Therapy-related myelodysplastic syndrome	172	1.7%	0.1	78	1.4%	0.1	94	2.0%	0.1	
Myelodysplastic syndrome, NOS	5159	50.2%	1.8	2789	50.1%	2.5	2370	50.4%	1.4	
Chronic myeloproliferative disorders (CMD)	6123	100.0%	2.1	3240	100.0%	2.6	2883	100.0%	1.8	
Polycythemia vera	2553	41.7%	0.9	1499	46.3%	1.1	1054	36.6%	0.7	
Chronic myeloproliferative disease, NOS	1185	19.4%	0.4	642	19.8%	0.5	543	18.8%	0.3	
Myelosclerosis with myeloid metaplasia	694	11.3%	0.2	402	12.4%	0.3	292	10.1%	0.2	
Essential thrombocythemia	1568	25.6%	0.5	627	19.4%	0.5	941	32.6%	0.6	
Chronic neutrophilic leukemia	-	-	-	-	-	-	-	-	-	
Hypereosinophilic syndrome	109	1.8%	0.0	62	1.9%	0.0	47	1.6%	0.0	
Chronic myelomonocytic leukemia (CMML)	1019	100.0%	0.4	617	100.0%	0.5	402	100.0%	0.2	

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Statistic not shown due to fewer than 16 cases during the time period.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

а

### Table XXX-2

#### MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOPROLIFERATIVE DISORDERS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA

Age-Adjusted Incidence Rates<sup>a</sup> for the 17 SEER Geographic Areas by Age and Race, 2001-2004

	<u>Bo</u> th	Sexes	Males		Females	
Site	Rate	Count	Rate	Count	Rate	Count
Myelodysplastic syndromes (MDS)						
By age						
<40	0.2	272	0.2	144	0.2	128
40-49	0.2	360	0.8	178	0.8	182
50-59	2.1	748	2.3	389	2.0	359
60-69	7.8	1611	9.4	904	6.5	707
70-79	22.5	3446	30.4	1983	16.6	1463
80+	39.3	3831	57.7	1966	29.5	1865
By race	59.5	2021	57.7	1900	29.5	1902
All Races	3.6	10268	4.9	5564	2.9	4704
White	3.0	8741	4.9	4804	2.9	
						3937
Black	3.3	748	4.0	350	2.9	398
Asian/Pacific Islander	2.8	579	3.4	300	2.3	279
American Indian/Alaska Native <sup>b</sup>	2.1	27	-	-	2.3	17
Hispanic <sup>c</sup>	2.8	730	3.3	376	2.4	354
Chronic myeloproliferative disorders	(CMD)					
By age	. ,					
<40	0.2	417	0.3	230	0.2	187
40-49	1.3	616	1.5	354	1.1	262
50-59	2.6	918	3.2	555	2.0	363
60-69	6.1	1263	7.4	713	5.0	550
70-79	10.9	1668	13.0	854	9.2	814
80+	12.7	1241	15.6	534	11.2	707
By race	12.7	1211	10.0	551	11.2	707
All Races	2.1	6123	2.6	3240	1.8	2883
White	2.1	5008	2.6	2690	1.8	2318
Black	2.1	535	2.0	260	1.0	275
Asian/Pacific Islander	1.5	360	1.7	177	1.4	183
American Indian/Alaska Native <sup>b</sup>	1.5	19	1.7	± / /	1.4	103
	1.1	470	- 1.8	250	-	220
Hispanic <sup>c</sup>	1.5	470	1.8	250	1.3	220
Chronic myelomonocytic leukemia (CMM	С)					
By age						
<40	-	-	-	-	-	-
40-49	-	-	-	-	-	-
50-59	0.2	53	0.2	31	0.1	22
60-69	0.8	173	1.3	124	0.4	49
70-79	2.5	377	3.8	247	1.5	130
80+	4.0	390	5.9	203	2.9	187
By race						/
All Races	0.4	1019	0.5	617	0.2	402
White	0.4	898	0.6	537	0.3	361
Black	0.1	64	0.5	41	0.2	23
Asian/Pacific Islander	0.3	42	0.3	29	-	
American Indian/Alaska Native <sup>b</sup>	0.2	42	0.5	- 29	_	_
Hispanic <sup>c</sup>	0.2	58	0.4	36	0.2	22
птерантс	0.2	20	0.4	20	0.2	22

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
Statistic not shown due to fewer than 16 cases during the time period.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Convige Delivery Area) equation

- Service Delivery Area) counties. с
- Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.